Compare DMRA & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DMRA | INSP |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2020 | 2018 |
| Metric | DMRA | INSP |
|---|---|---|
| Price | $31.80 | $57.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 16 |
| Target Price | $43.00 | ★ $94.00 |
| AVG Volume (30 Days) | 372.2K | ★ 754.5K |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 121.48 | ★ 179.43 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $82,050,000.00 |
| Revenue This Year | N/A | $8.02 |
| Revenue Next Year | N/A | $8.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 62.18 |
| 52 Week Low | $16.50 | $38.91 |
| 52 Week High | $34.89 | $147.03 |
| Indicator | DMRA | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 60.76 | 57.94 |
| Support Level | $22.71 | $52.37 |
| Resistance Level | $31.77 | $59.40 |
| Average True Range (ATR) | 1.63 | 2.22 |
| MACD | 0.02 | -0.25 |
| Stochastic Oscillator | 87.75 | 50.01 |
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.